Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A4I Antagonist in Relapsing Multiple Sclerosis
NCT00104143Phase 2Withdrawn
- Sponsor
- Roche
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of RO0506997 in multiple sclerosis (MS) (4 arms), sponsored by Roche. Primary endpoint: Cumulative number of new gadolinium-enhancing MRI lesions. Planned start Oct 2007; status: withdrawn.
02
Drugs
RO0506997
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00104143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00104143.